Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

Patients completing the EFC6049 (HMR1726D/3001) study are given the opportunity to continue
in the extension study;

- patients receiving teriflunomide 7 mg or 14 mg are blindly maintained on the same dose
of teriflunomide.

- patients receiving placebo are randomized to teriflunomide 7 mg or 14 mg.

The study period per patient is broken down as follows:

- Double-blind treatment: up to a maximum of 288 weeks or until teriflunomide is
commercially available in the country where patient lives,

- Post-washout follow-up: 4 weeks after last treatment intake. No post-washout follow up
if patient continues on teriflunomide treatment by obtaining it's commercial form after
end of the study.

The total duration of the extension is 292 weeks (about 6 years) from the first patient
enrolled or until teriflunomide is commercially available in the country where patient
lives.

Inclusion Criteria:

- Patient who has completed the previous double-blind placebo-controlled study EFC6049
and who does not meet criteria for treatment withdrawal.

- Willingness to participate in a long-term safety/efficacy trial.

Exclusion Criteria:

- Any known condition or circumstance that would prevent in the investigator's opinion,
compliance or completion of the study.

The above information is not intended to contain all considerations relevant to a
patient's potential participation in a clinical trial.